Baylor University Medical Center, part of Baylor Scott and White Health, and Texas Oncology have announced that they are now offering CAR-T cancer therapy to treat diffuse large B-cell lymphoma (DLBCL).
The providers are the first in the US to treat patients with the only CAR-T (Chimeric Antigen Receptor T) cell therapy approved by the Food and Drug Administration (FDA) to treat this form of cancer. CAR-T is a personalised therapy where a patient’s immune cells are removed from their body, genetically reprogrammed, then infused back into the them to identify and attack their cancer as a one-time treatment.
The CAR-T therapy offered at Baylor University Medical Center reprograms the patient’s cells to specifically attack DLBCL, the most common and aggressive form of lymphoma.
“This could be a game-changing treatment for patients whose cancer has not responded to other treatment options,” said Dr Yair Levy, Medical Oncologist at Texas Oncology and Medical Director of hematologic malignancy clinical research at Baylor University Medical Center. “It is an important advancement in cancer care to bring this next-generation treatment to North Texas that has shown promising results in treating patients with large B-cell lymphoma during both clinical trials and active treatments to date.”